NCT07617428

Brief Summary

This observational study aims to evaluate the practicality of a novel multifunctional intraoperative blood loss monitoring system in real-world surgical settings. The primary questions it seeks to address are: Using the direct measurement method as the reference standard, what is the magnitude of measurement error of the monitoring system, and does it tend to overestimate or underestimate blood loss? Does the monitoring system demonstrate superior accuracy compared with visual estimation, the gravimetric method, and the hemoglobin concentration-based method? During surgery, intraoperative blood loss will be measured simultaneously using five approaches: the novel multifunctional monitoring system, the direct measurement method, visual estimation, the gravimetric method, and the hemoglobin concentration method. These measurements will be conducted without interfering with the surgical procedure.

Trial Health

55
Monitor

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
120

participants targeted

Target at P50-P75 for all trials

Timeline
Completed

Started Sep 2025

Shorter than P25 for all trials

Geographic Reach
1 country

3 active sites

Status
enrolling by invitation

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

September 10, 2025

Completed
8 months until next milestone

First Submitted

Initial submission to the registry

May 5, 2026

Completed
25 days until next milestone

Primary Completion

Last participant's last visit for primary outcome

May 30, 2026

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

May 30, 2026

Completed
2 days until next milestone

First Posted

Study publicly available on registry

June 1, 2026

Completed
Last Updated

June 3, 2026

Status Verified

April 1, 2026

Enrollment Period

9 months

First QC Date

May 5, 2026

Last Update Submit

May 31, 2026

Conditions

Keywords

blood lossClinical ValidationMonitoring Equipment

Outcome Measures

Primary Outcomes (1)

  • Absolute error of the automatic intraoperative blood loss monitor compared with the direct measurement method

    Absolute error is defined as the numerical difference between intraoperative blood loss measured by the automatic intraoperative blood loss monitor and intraoperative blood loss measured by the direct measurement method. A positive value indicates that the monitor overestimates blood loss compared with the direct measurement method, whereas a negative value indicates underestimation. Unit of Measure: Milliliters (mL)

    At the end of surgery

Secondary Outcomes (7)

  • Percentage error of the automatic intraoperative blood loss monitor compared with the direct measurement method

    At the end of surgery

  • Absolute error of visual estimation compared with the direct measurement method

    At the end of surgery

  • Absolute error of the gravimetric method compared with the direct measurement method

    At the end of surgery

  • Absolute error of the hemoglobin concentration-based method compared with the direct measurement method

    24 hours after surgery

  • Intraclass correlation coefficient between the automatic intraoperative blood loss monitor and the direct measurement method

    At the end of surgery

  • +2 more secondary outcomes

Study Arms (1)

Self-controlled

This study includes a single self-controlled cohort of patients undergoing urological and general surgical procedures. All participants will undergo simultaneous intraoperative blood loss assessment using five different methods within the same surgical procedure: a novel multifunctional intraoperative blood loss monitoring system, the direct measurement method (reference standard), visual estimation, the gravimetric method, and the hemoglobin concentration-based method. No intervention is applied in this observational study. All measurements are performed according to a predefined protocol and do not interfere with the standard surgical workflow. The purpose of this design is to enable within-subject comparison of measurement accuracy across different methods under identical clinical conditions.

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

The study population will be recruited from adult patients undergoing elective urological and general surgical procedures at two tertiary hospitals in China, including Lanzhou University Second Hospital and Lanzhou University First Hospital. Participants will be selected from routine clinical practice settings where intraoperative blood loss monitoring is required. This population represents adult surgical patients managed under standard perioperative care, providing a real-world clinical context for evaluating intraoperative blood loss measurement methods.

You may qualify if:

  • Patients undergoing elective urological or general surgical procedures
  • Age 18 years or older
  • Preoperative hemoglobin concentration available
  • Intraoperative blood loss assessment required during surgery

You may not qualify if:

  • Patients with incomplete intraoperative blood loss measurement data,
  • Severe hemolysis or other conditions that may affect hemoglobin measurement
  • Emergency surgery
  • Intraoperative blood loss assessment required during surgery 24 hours after surgery
  • Refusal to participate, when applicable

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (3)

Gansu Provincial People's Hospital

Lanzhou, Gansu, 730030, China

Location

Lanzhou University Frist Hospital

Lanzhou, Gansu, 730030, China

Location

Lanzhou University Second Hospital

Lanzhou, Gansu, 730030, China

Location

MeSH Terms

Conditions

Hemorrhage

Condition Hierarchy (Ancestors)

Pathologic ProcessesPathological Conditions, Signs and Symptoms

Study Design

Study Type
observational
Observational Model
CASE ONLY
Time Perspective
PROSPECTIVE
Target Duration
1 Day
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Professor; Chief Physician

Study Record Dates

First Submitted

May 5, 2026

First Posted

June 1, 2026

Study Start

September 10, 2025

Primary Completion

May 30, 2026

Study Completion

May 30, 2026

Last Updated

June 3, 2026

Record last verified: 2026-04

Locations